NASDAQ:TNYA • US87990A1060
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TENAYA THERAPEUTICS INC (TNYA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-18 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-12-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-03-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-12 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-03-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-18 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-10-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 1,456.12% | N/A 210.48% | N/A 238.47% | N/A 76.62% | N/A 104.32% | N/A 15.05% | N/A 15.08% | ||||||||
| EBITDA YoY % growth | -25.72M | -36.43M -41.64% | -69.85M -91.74% | -119.15M -70.58% | -122.506M -2.82% | -107.48M 12.27% | -84.895M 21.01% | N/A -21.36% | N/A -28.54% | N/A -28.55% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -27.71M | -38.91M -40.42% | -72.81M -87.12% | -125.62M -72.53% | -131.193M -4.44% | -115.948M 11.62% | -93.331M 19.51% | N/A 2.64% | N/A -21.16% | N/A 228.42% | N/A 761.51% | N/A 79.39% | N/A 113.46% | N/A 15.18% | N/A 15.30% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.79 70.82% | -1.67 40.14% | -1.32 20.96% | -0.62 53.03% | N/A 24.05% | N/A 118.41% | N/A 2,141.18% | N/A 80.05% | N/A 75.22% | N/A 117.64% | N/A 14.60% | N/A 14.74% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.09 62.97% | -0.13 5.29% | -0.14 -13.33% | -0.14 -16.17% |
| Revenue Q2Q % growth | 10.2M | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.044M 56.26% | -25.844M -7.32% | -27.244M -30.13% | -28.825M -38.75% |
All data in USD
14 analysts have analysed TNYA and the average price target is 9.18 USD. This implies a price increase of 1131.22% is expected in the next year compared to the current price of 0.7456.
TENAYA THERAPEUTICS INC (TNYA) will report earnings on 2026-05-01.
The consensus EPS estimate for the next earnings of TENAYA THERAPEUTICS INC (TNYA) is -0.09 USD and the consensus revenue estimate is 10.20M USD.
The number of analysts covering TENAYA THERAPEUTICS INC (TNYA) is 14.